JP2019513143A - 新規塩類および結晶 - Google Patents

新規塩類および結晶 Download PDF

Info

Publication number
JP2019513143A
JP2019513143A JP2018550823A JP2018550823A JP2019513143A JP 2019513143 A JP2019513143 A JP 2019513143A JP 2018550823 A JP2018550823 A JP 2018550823A JP 2018550823 A JP2018550823 A JP 2018550823A JP 2019513143 A JP2019513143 A JP 2019513143A
Authority
JP
Japan
Prior art keywords
salt
iti
salts
diffraction pattern
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018550823A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513143A5 (cg-RX-API-DMAC10.html
Inventor
ペン・リ
エドウィン・アレット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of JP2019513143A publication Critical patent/JP2019513143A/ja
Publication of JP2019513143A5 publication Critical patent/JP2019513143A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2018550823A 2016-03-28 2017-03-28 新規塩類および結晶 Pending JP2019513143A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662314326P 2016-03-28 2016-03-28
US62/314,326 2016-03-28
PCT/US2017/024562 WO2017172784A1 (en) 2016-03-28 2017-03-28 Novel salts and crystals

Publications (2)

Publication Number Publication Date
JP2019513143A true JP2019513143A (ja) 2019-05-23
JP2019513143A5 JP2019513143A5 (cg-RX-API-DMAC10.html) 2020-04-30

Family

ID=59965145

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018550823A Pending JP2019513143A (ja) 2016-03-28 2017-03-28 新規塩類および結晶

Country Status (4)

Country Link
US (1) US10654854B2 (cg-RX-API-DMAC10.html)
EP (1) EP3436455A4 (cg-RX-API-DMAC10.html)
JP (1) JP2019513143A (cg-RX-API-DMAC10.html)
WO (1) WO2017172784A1 (cg-RX-API-DMAC10.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021100852A1 (ja) * 2019-11-21 2021-05-27 キリンホールディングス株式会社 結晶スポンジ法による構造解析のための結晶構造解析用試料の調製方法
JP2021089263A (ja) * 2019-11-21 2021-06-10 キリンホールディングス株式会社 結晶スポンジ法による構造解析のための結晶構造解析用試料の調製方法
US12253482B2 (en) 2019-11-01 2025-03-18 Kirin Holdings Kabushiki Kaisha Method for determining structure of substance in multicomponent sample

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2725342C (en) * 2008-05-27 2024-02-20 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for sleep disorders and other disorders
US9428506B2 (en) 2012-04-14 2016-08-30 Intra-Cellular Therapies, Inc. Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders
RU2743513C2 (ru) 2016-01-26 2021-02-19 Интра-Селлулар Терапиз, Инк. Органические соединения
HUE057055T2 (hu) 2016-08-09 2022-04-28 Teva Pharmaceuticals Int Gmbh Lumateperon-ditozilátsó szilárd halmazállapotú formái
EP3600325A4 (en) 2017-03-24 2021-01-06 Intra-Cellular Therapies, Inc. UNIQUE COMPOSITIONS AND PROCESSES
WO2018189646A1 (en) 2017-04-10 2018-10-18 Dr. Reddy's Laboratories Limited AMORPHOUS FORM AND SOLID DISPERSIONS OF LUMATEPERONE p-TOSYLATE
JP7224333B2 (ja) 2017-07-26 2023-02-17 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2019067591A1 (en) 2017-09-26 2019-04-04 Intra-Cellular Therapies, Inc. NEW SALTS AND CRYSTALS
WO2019178484A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
AU2019240226B2 (en) 2018-03-23 2024-11-28 Intra-Cellular Therapies, Inc. Organic compounds
SMT202600133T1 (it) 2018-03-23 2026-05-12 Intra Cellular Therapies Inc Composti organici
CN112105349A (zh) * 2018-04-12 2020-12-18 阿纳韦克斯生命科学公司 A2-73结晶多晶型物质组合物及其使用方法
BR112020024885A2 (pt) 2018-06-06 2021-03-09 Intra-Cellular Therapies, Inc. Novos sais e cristais
EP3801527B1 (en) 2018-06-08 2025-02-19 Intra-Cellular Therapies, Inc. Fused gamma-carbolines for acute treatment of anxiety or depression
RS67906B1 (sr) 2018-06-11 2026-04-30 Intra Cellular Therapies Inc Sinteza supstituisanih heterociklično fuzionisanih gama-karbolina
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
AU2019328528B2 (en) 2018-08-31 2025-01-23 Intra-Cellular Therapies, Inc. Novel methods
WO2020047408A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
WO2020112941A2 (en) 2018-11-27 2020-06-04 Teva Czech Industries S.R.O Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof
IL315005B2 (en) 2018-12-17 2026-04-01 Intra Cellular Therapies Inc Substituted heterocycle fused gamma-carbolines synthesis
ES3047409T3 (en) 2018-12-17 2025-12-03 Intra Cellular Therapies Inc Substituted heterocycle fused gamma-carbolines synthesis
KR20210104785A (ko) 2018-12-17 2021-08-25 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
JP7377871B2 (ja) 2018-12-21 2023-11-10 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
US12331052B2 (en) 2018-12-21 2025-06-17 Intra-Cellular Therapies, Inc. Organic compounds
WO2020182978A1 (en) 2019-03-13 2020-09-17 Sandoz Ag Crystalline salt of a 5-ht2a receptor antagonist
EP4134101A1 (en) 2019-07-07 2023-02-15 Intra-Cellular Therapies, Inc. Deuterated lumateperone for the treatment of the bipolar ii disorder
JP2022549335A (ja) 2019-09-25 2022-11-24 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規方法
WO2021119334A1 (en) 2019-12-11 2021-06-17 Intra-Cellular Therapies, Inc. Organic compound
TWI918905B (zh) 2021-03-26 2026-03-21 大陸商上海雲晟研新生物科技股份有限公司 盧美哌隆藥用鹽、製備方法、含其的藥物組合物及應用
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
US20250352469A1 (en) 2024-05-16 2025-11-20 Intra-Cellular Therapies, Inc. Novel compositions, devices, and methods

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003502331A (ja) * 1999-06-15 2003-01-21 ブリストル−マイヤーズ スクイブ ファーマ カンパニー 置換複素環縮合ガンマーカルボリン
JP2010521464A (ja) * 2007-03-12 2010-06-24 イントラ−セルラー・セラピーズ・インコーポレイテッド 置換ヘテロ環縮合ガンマ−カルボリンの合成
JP2011513485A (ja) * 2008-03-12 2011-04-28 イントラ−セルラー・セラピーズ・インコーポレイテッド 置換ヘテロ環縮合ガンマ−カルボリン類固体
JP2011523949A (ja) * 2008-05-27 2011-08-25 イントラ−セルラー・セラピーズ・インコーポレイテッド 睡眠障害および他の障害のための方法および組成物
JP2012517999A (ja) * 2009-02-18 2012-08-09 ドン ア ファーマシューティカル カンパニー リミテッド ウデナフィル酸付加塩、その製造方法、およびこれを含む薬学的組成物
JP2013525352A (ja) * 2010-04-22 2013-06-20 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2490813A (en) 1944-11-29 1949-12-13 Standard Oil Co Continuous process for making aryl amines
US3299078A (en) 1962-10-01 1967-01-17 Smith Kline French Lab Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines
US3813392A (en) 1969-06-09 1974-05-28 J Sellstedt Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds
US4238607A (en) 1972-06-19 1980-12-09 Endo Laboratories Inc. Pyridopyrrolo benzheterocycles
US4115577A (en) 1972-06-19 1978-09-19 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4183936A (en) 1972-06-19 1980-01-15 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US3914421A (en) 1972-06-19 1975-10-21 Endo Lab Pyridopyrrolobenzheterocycles for combatting depression
US4219550A (en) 1978-11-09 1980-08-26 E. I. Du Pont De Nemours And Company Cis- and trans- octahydropyridopyrrolobenzheterocycles
US4522944A (en) 1982-12-23 1985-06-11 Erba Farmitalia Carboxamido-derivatives of 5H-1,3,4-thiadiazolo[3,2-a]pyrimidines, compositions and use
ES2058068T3 (es) 1986-03-19 1994-11-01 Kumiai Chemical Industry Co Derivados de 5h-1,3,4-tiadiazol-(3,2-a)-pirimidin-5-ona y compuestos fungicidas con contenido en dichos derivados.
ATE91129T1 (de) 1986-04-07 1993-07-15 Kumiai Chemical Industry Co 5h-1,3,4-thiadiazolo(3,2-a>pyrimidin-5-onderivate und diese enthaltende gartenbau- und landwirtschaftliche fungizidmittel.
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5576460A (en) 1994-07-27 1996-11-19 Massachusetts Institute Of Technology Preparation of arylamines
US5648542A (en) 1996-02-29 1997-07-15 Xerox Corporation Arylamine processes
US5654482A (en) 1996-02-29 1997-08-05 Xerox Corporation Triarylamine processes
US5648539A (en) 1996-02-29 1997-07-15 Xerox Corporation Low temperature arylamine processes
US5847166A (en) 1996-10-10 1998-12-08 Massachusetts Institute Of Technology Synthesis of aryl ethers
US5723671A (en) 1997-01-30 1998-03-03 Xerox Corporation Arylamine processes
US5723669A (en) 1997-01-30 1998-03-03 Xerox Corporation Arylamine processes
US5705697A (en) 1997-01-30 1998-01-06 Xerox Corporation Arylamine processes
US6323366B1 (en) 1997-07-29 2001-11-27 Massachusetts Institute Of Technology Arylamine synthesis
GB2328686B (en) 1997-08-25 2001-09-26 Sankio Chemical Co Ltd Method for producing arylamine
WO1999018057A1 (en) 1997-10-06 1999-04-15 Massachusetts Institute Of Technology Preparation of diaryl ether by condensation reactions
US6235936B1 (en) 1998-02-26 2001-05-22 Massachusetts Institute Of Technology Metal-catalyzed arylations of hydrazines, hydrazones, and related substrates
EP1058678B1 (en) 1998-02-26 2002-12-11 Massachusetts Institute of Technology Metal-catalyzed arylations and vinylations of hydrazines, hydrazones, hydroxylamines and oximes
US5902901A (en) 1998-05-07 1999-05-11 Xerox Corporation Arylamine processes
US6307087B1 (en) 1998-07-10 2001-10-23 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US7223879B2 (en) 1998-07-10 2007-05-29 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
JP5035813B2 (ja) 1998-07-10 2012-09-26 マサチューセッツ インスティテュート オブ テクノロジー 金属用のリガンドおよびそれらに基づいて改善された金属触媒法
US6395916B1 (en) 1998-07-10 2002-05-28 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US20010008942A1 (en) 1998-12-08 2001-07-19 Buchwald Stephen L. Synthesis of aryl ethers
US6407092B1 (en) 1999-04-23 2002-06-18 Pharmacia & Upjohn Company Tetracyclic azepinoindole compounds
PE20010052A1 (es) 1999-04-23 2001-01-27 Upjohn Co Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
US6541639B2 (en) 2000-07-26 2003-04-01 Bristol-Myers Squibb Pharma Company Efficient ligand-mediated Ullmann coupling of anilines and azoles
RU2003121304A (ru) 2000-12-20 2005-01-27 Бристол-Маерс Сквибб Компани (Us) Замещенные пиридоиндолы в качестве агонистов и антагонистов серотонина
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
KR20030092107A (ko) 2001-04-24 2003-12-03 메사추세츠 인스티튜트 오브 테크놀로지 탄소-헤테로원자 및 탄소-탄소 결합을 형성하는 구리-촉매방법
US6888032B2 (en) 2002-08-02 2005-05-03 Massachusetts Institute Of Technology Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
WO2004056324A2 (en) 2002-12-19 2004-07-08 Bristol-Myers Squibb Company Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
AU2004259741A1 (en) 2003-07-21 2005-02-03 Smithkline Beecham Corporation (2S,4S)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof
US7109064B2 (en) 2003-12-08 2006-09-19 Semiconductor Components Industries, L.L.C. Method of forming a semiconductor package and leadframe therefor
JP2005259113A (ja) 2004-02-12 2005-09-22 Ricoh Co Ltd プロセス編集装置、プロセス管理装置、プロセス編集プログラム、プロセス管理プログラム、記録媒体、プロセス編集方法及びプロセス管理方法
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
US7592454B2 (en) 2004-04-14 2009-09-22 Bristol-Myers Squibb Company Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists
MX2007006896A (es) 2004-12-15 2007-06-26 Hoffmann La Roche Fenil-metanonas bi- y triciclicas sustituidas como inhibidores del transportador 1 de glicina (glyt-1) para el tratamiento de la enfermedad de alzheimer.
BRPI0607239A2 (pt) 2005-01-25 2009-08-25 Celgene Corp usos de uma quantidade terapeuticamente ou profilaticamente eficaz de 4-amino-2-(3-metil-2,6-dioxopiperidin-3-il)-isoindol-1,3-d iona, de (3r)-4-amino-2-(3-metil-2,6-dioxopiperidin-3-il)-isoindol- 1,3-diona, e de (3s)-4-amino-2-(3-metil-2,6-dioxopiperidin-3-il)-isoindol- 1,3-diona, ou um sal ou solvato farmaceuticamente aceitável das mesmas, composição farmacêutica, e, forma de dosagem unitária simples
EP1919287A4 (en) 2005-08-23 2010-04-28 Intra Cellular Therapies Inc ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY
JP2009523734A (ja) 2006-01-13 2009-06-25 ワイス ５−ヒドロキシトリプタミン受容体のためのリガンドとしてのスルホニル置換された１ｈ−インドール
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
CA2719824A1 (en) 2007-08-01 2009-02-05 Medivation Neurology, Inc. Methods and compositions for treating schizophrenia using antipsychotic combination therapy
US9428506B2 (en) 2012-04-14 2016-08-30 Intra-Cellular Therapies, Inc. Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders
WO2014145192A1 (en) 2013-03-15 2014-09-18 Intra-Cellular Therapies, Inc. Organic compounds
KR102967223B1 (ko) 2013-12-03 2026-05-19 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
WO2017172811A1 (en) * 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel co-crystals

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003502331A (ja) * 1999-06-15 2003-01-21 ブリストル−マイヤーズ スクイブ ファーマ カンパニー 置換複素環縮合ガンマーカルボリン
JP2010521464A (ja) * 2007-03-12 2010-06-24 イントラ−セルラー・セラピーズ・インコーポレイテッド 置換ヘテロ環縮合ガンマ−カルボリンの合成
JP2011513485A (ja) * 2008-03-12 2011-04-28 イントラ−セルラー・セラピーズ・インコーポレイテッド 置換ヘテロ環縮合ガンマ−カルボリン類固体
JP2011523949A (ja) * 2008-05-27 2011-08-25 イントラ−セルラー・セラピーズ・インコーポレイテッド 睡眠障害および他の障害のための方法および組成物
JP2012517999A (ja) * 2009-02-18 2012-08-09 ドン ア ファーマシューティカル カンパニー リミテッド ウデナフィル酸付加塩、その製造方法、およびこれを含む薬学的組成物
JP2013525352A (ja) * 2010-04-22 2013-06-20 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PHARM TECH JAPAN, vol. 18, no. 10, JPN7014002019, 2002, pages 1629 - 1644, ISSN: 0004451842 *
小嶌隆史ら: "医薬品開発における開発形態の最適化", ファルマシア, vol. 52(5), JPN6021047939, 2016, pages 387 - 391, ISSN: 0004656496 *
平山令明, 有機化合物結晶作製ハンドブック, JPN6014035600, 2008, pages 17 - 23, ISSN: 0004451843 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12253482B2 (en) 2019-11-01 2025-03-18 Kirin Holdings Kabushiki Kaisha Method for determining structure of substance in multicomponent sample
WO2021100852A1 (ja) * 2019-11-21 2021-05-27 キリンホールディングス株式会社 結晶スポンジ法による構造解析のための結晶構造解析用試料の調製方法
JP2021089263A (ja) * 2019-11-21 2021-06-10 キリンホールディングス株式会社 結晶スポンジ法による構造解析のための結晶構造解析用試料の調製方法
JP7213839B2 (ja) 2019-11-21 2023-01-27 キリンホールディングス株式会社 結晶スポンジ法による構造解析のための結晶構造解析用試料の調製方法

Also Published As

Publication number Publication date
EP3436455A4 (en) 2019-09-04
WO2017172784A1 (en) 2017-10-05
US20190112309A1 (en) 2019-04-18
EP3436455A1 (en) 2019-02-06
US10654854B2 (en) 2020-05-19

Similar Documents

Publication Publication Date Title
JP6997718B2 (ja) 新規共結晶
US10654854B2 (en) Salts and crystals of ITI-007
ES3052998T3 (en) Crystalline hydrochloride salt of lumateperone
CN112384218B (zh) 盐和晶体
RU2470935C2 (ru) Бензодиазепиновые соли кратковременного действия и их полиморфные формы
JP2009542787A (ja) 短時間作用型ベンゾジアゼピンの塩およびその多型形態
JP2023540506A (ja) 新規の塩、結晶および共結晶
JP6161538B2 (ja) 結晶形及びその製造方法
HK40028178A (en) Novel salts and crystals
JP2015534989A (ja) ｛ｓ−３−（４−アミノ−１−オキソ−イソインドリン−２−イル）（ピペリジン−３，４，４，５，５−ｄ５）−２，６−ジオン｝の固体形態
HK40046696A (en) Novel salts and crystals
NZ728634B2 (en) Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200319

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210601

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211207